Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16816005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Invasive aspergillosis seems to be on the rise, especially in immunocompromised children. Historically, only systemic amphotericin B has been effective against Aspergillus. Development of newer antifungal agents, such as voriconazole and caspofungin, has improved the treatment options available for aspergillosis, although no definitive management strategy has been established. Here we describe the use of topical voriconazole combined with systemic antifungal agents for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.
Medical subject headings
- Antifungal Agents
- Aspergillosis
- Aspergillus flavus
- Bone Marrow Transplantation
- Dermatomycoses
- Postoperative Complications
- Pyrimidines
- Triazoles